Impact of hemodialysis solutions containing different levels of molecular hydrogen (H2) on the patient-reported outcome of fatigue
Susumu Uemura, Yoshitaka Kegasa, Keigo Tada, Taichi Tsukahara, Shigeru Kabayama, Tae Yamamoto, Mariko Miyazaki, Joji Takada, Masaaki Nakayama · Renal Replacement Therapy · 2022
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 105 patients, amelioration of the patient-reported outcome of fatigue might be influenced by H₂ levels in the HD solution, and the optimal H₂ level in the dialysate needs to be elucidated in consideration of clinical type of fatigue and BP control status. At the 8th week, 64 patients (61%) presented absence of or decrease in the NRS score of fatigue, while the rest of patients did not present the decrease in NRS (the non-improved: 39%). These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence blood-pressure regulation.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 105 patients. Amelioration of the patient-reported outcome of fatigue might be influenced by H₂ levels in the HD solution, and the optimal H₂ level in the dialysate needs to be elucidated in consideration of clinical type of fatigue and BP control status. At the 8th week, 64 patients (61%) presented absence of or decrease in the NRS score of fatigue, while the rest of patients did not present the decrease in NRS (the non-improved: 39%).
What the Researchers Studied
The researchers studied 105 patients. The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 8 weeks. Amelioration of the patient-reported outcome of fatigue might be influenced by H₂ levels in the HD solution, and the optimal H₂ level in the dialysate needs to be elucidated in consideration of clinical type of fatigue and BP control status. At the 8th week, 64 patients (61%) presented absence of or decrease in the NRS score of fatigue, while the rest of patients did not present the decrease in NRS (the non-improved: 39%).
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence blood-pressure regulation and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 105 patients. The reported sample size was 105. The study used a human clinical study. The reported treatment duration was 8 weeks.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base. The original scholarly source is available at https://link.springer.com/article/10.1186/s41100-022-00422-7/fulltext.html.